Non-interventional study to estimate the effectiveness of Arexvy vaccine in preventing respiratory syncytial virus-associated lower respiratory tract disease hospitalization in adults>=60 years: a test negative design
This observational study aims to assess the vaccine effectiveness of Arexvy in preventing laboratory-confirmed RSV-acute respiratory infection (ARI)/LRTD hospitalization in adults>=60 years at Kaiser Permanente Southern California, using a test-negative design.